Gamida Cell Ltd.

Have you ever been curious about what hematopoietic stem cell transplant is used to treat? Stem cell transplants might be the only potential cure for patients with certain types of blood cancers. Acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS) and non-Hodgkin lymphoma are examples of diseases that may be treated with a transplant; however, not all patients with these diseases will need or be eligible for a transplant.

Be The Match shares information about blood cancers that can be treated with a transplant: https://bethematch.org/transplant-basics/how-blood-stem-cell-transplants-work/diseases-treatable-by-transplants/

Note: Gamida Cell is not responsible for and does not control the content found within third-party websites.

For patients with blood cancer, their individual treatment journey may ultimately lead to allogeneic stem cell transplant. Once allogeneic stem cell transplant is considered as an option for a patient, there are still many decisions to be made at this point in the process.

One important decision is selecting a donor source for transplant. A fully matched stem cell donor, which may be found via a related or an unrelated donor in the registry, involves matching of the cell’s human leukocyte antigens (HLAs), and is usually considered the most attractive option for patients. But what do you do if you don’t have a full match available?

This is where options involving HLA matching from partially matched donor sources, cord blood transplant and innovative cell therapies can offer a strong alternative.

Newer cell therapy technologies allow potentially greater access to stem cell transplant for patients who otherwise may not have been able to access transplant, including patients from diverse racial and ethnic backgrounds where finding an exact matched donor may be more difficult.

Ongoing innovation continues to create new paths to help ensure stem cell transplant offers more patients the opportunity to recover, with fewer risks, and to live their lives to the fullest.

Happy Holidays from the Gamida Cell team! However you celebrate, may you and your loved ones experience the gifts of peace and health this holiday season.

Gamida Cell works to turn cells into powerful therapeutics. Our proprietary nicotinamide (NAM) technology expands cells as it enhances cellular functionality and phenotype, allowing us to create allogeneic cell therapy products that are potentially curative for patients with cancer.

NAM enhances and expands hematopoietic stem cells, which show increased metabolic fitness and homing and retention in the bone marrow. For natural killer cells (NK), recent published findings in Science Translational Medicine show that NAM may increase their cytotoxic effects and resilience under oxidative stress, yielding highly functional cells that can potentially resist exhaustion when fighting tumors. https://www.science.org/doi/10.1126/scitranslmed.ade3341

Note: Gamida Cell is not responsible for and does not control the content found within third-party websites.